<DOC>
	<DOCNO>NCT02563899</DOCNO>
	<brief_summary>This double blind ( sponsor unblind ) , repeat dose , randomize , parallel group , placebo control study ass pharmacokinetic parameter , safety , tolerability , clinical effect topically apply umeclidinium follow daily topical administration axilla 14 day subject primary axillary hyperhidrosis . This study determine whether topically apply umeclidinium decrease hyperhidrosis without systemic anticholinergic effect ( ie . range low obtain inhaled route ) high possible concentration . Subjects dose site staff night immediately bedtime 14 day . Subjects complete gravimetric Hyperhidrosis Disease Severity Scale ( HDSS ) measurement , patient report outcome ( PRO ) , safety assessment , and/or pharmacokinetic sampling . Follow visit occur day 15 , 16 , 19 , 23 28 . The total duration study approximately 6 8 week . The study plan enroll approximately 24 subject .</brief_summary>
	<brief_title>Pharmacokinetic , Safety , Tolerability , Clinical Effect Topical Umeclidinium Primary Axillary Hyperhidrosis</brief_title>
	<detailed_description />
	<mesh_term>Hyperhidrosis</mesh_term>
	<criteria>Between 18 65 year age inclusive , time signing informed consent . A Hyperhidrosis Disease Severity Scale ( HDSS ) score 3 4 . A diagnosis primary , axillary hyperhidrosis , define excessive , bilateral , axillary sweating least 6 month duration without apparent cause least 1 follow characteristic : subject positive family history hyperhidrosis , hyperhidrosis bilateral relatively symmetrical , subject experience first episode hyperhidrosis 25 year age , subject experience cessation focal sweating sleep . A baseline gravimetric assessment least 50 milligram sweat produce rest axilla period 5 minute ( measurement repeat 2 time two different day , screen baseline visit , subject need qualify least one occasion ) . Male . A female eligible enter participate study : Nonchild bear potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal surgically sterile ) . Surgically sterile female define documented hysterectomy and/or bilateral oophorectomy tubal ligation . Postmenopausal female define amenorrhoeic great 1 year appropriate clinical profile , e.g. , age appropriate , &gt; 45 year , absence hormone replacement therapy . In questionable case woman &lt; 60 year age , blood sample simultaneous follicle stimulate hormone estradiol fall central laboratory 's postmenopausal reference range confirmatory . OR Child bear potential , negative pregnancy test screening , agree one follow acceptable contraceptive method use consistently correctly ( i.e. , accordance approve product label instruction physician ) duration study : abstinence ; oral contraceptive , either combined progestogen alone ; injectable progestogen ; implant levonorgestrel ; estrogenic vaginal ring ; percutaneous contraceptive patch ; intrauterine device ( IUD ) intrauterine system ( IUS ) meet standard operate procedure effectiveness criterion state product label ; male partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study , male sole partner subject ; double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) vaginal spermicidal agent ( foam/gel/film/cream/suppository If subject shave axilla remove hair mean within last 2 week , minimal irritation . Capable give sign informed consent include compliance prespecified requirement restriction . Unstable life threaten cardiac disease . In opinion investigator , use consider benefit likely outweigh risk condition : myocardial infarction unstable angina last 6 month , unstable life threaten cardiac arrhythmia require intervention last 3 month , New York Heart Association ( NYHA ) Class IV heart failure . Diagnosis narrowangle glaucoma , urinary retention , prostatic hypertrophy bladder neck obstruction opinion study investigator GlaxoSmithKline ( GSK ) Medical Monitor would prevent use anticholinergic therefore study participation . Irritation active infection axillary area , include sweat gland . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone investigator deem clinically significant ) . Alanine aminotransferase ( ALT ) &gt; 2 x Upper Limit Normal ( ULN ) bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) screening . Corrected QT Interval ( QTc ) &gt; 450 millisecond ( m ) QTc &gt; 480 ms subject Bundle Branch Block . The QTc QT interval correct heart rate accord Bazett 's formula ( QTcB ) , Fridericia 's formula ( QTcF ) , and/or another method , machineread manually overread . The specific formula use determine eligibility discontinuation individual subject determine prior initiation study . In word , several different formula use calculate QTc individual subject low QTc value use include discontinue subject trial . For purpose data analysis , QTcB , QTcF , another QT correction formula , composite available value QTc use . Prior surgical procedure hyperhidrosis . Axillary treatment radiofrequency microwave device . Treatment axillary iontophoresis within 4 week prior Baseline/Day 1 . Menopausal woman symptom menopause sweat flush within 3 year study . Used prohibited medication within indicate washout period . Any history allergy hypersensitivity anticholinergic/muscarinic receptor antagonist , sympathomimetic . Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . A positive prestudy drug/alcohol screen screen . A positive test Human Immunodeficiency Virus ( HIV ) antibody screen . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure 4 investigational medicinal product within 12 month prior first dose day . Any condition , judgment investigator , would put subject unacceptable risk participation study ( e.g. , subject renal failure ) . Subjects clinically significant abnormality laboratory value , accord investigator , study participation would put subject undue risk . Abnormal finding screen electrocardiogram ( ECG ) deem clinically significant Investigator . Women pregnant lactate plan become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Primary Axillary Hyperhidrosis</keyword>
	<keyword>GSK573719</keyword>
	<keyword>Hyperhidrosis Disease Severity Scale ( HDSS )</keyword>
	<keyword>Topical</keyword>
	<keyword>PRO</keyword>
	<keyword>Hyperhidrosis Symptom Severity Measure ( HSSM )</keyword>
	<keyword>Umeclidinium</keyword>
</DOC>